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The ancient drug salicylate 
directly activates AMP-activated 
protein kinase
Hawley et al., Science 2012; 336: 918–922; doi:10.1126/science.1215327
Salicylate, a hormone produced by plants in response to infec-
tion, has been used by humans to treat physical ailments for 
thousands of years. Aspirin and salsalate are commonly used 
synthetic derivatives that are rapidly converted to salicylate 
after ingestion. While the ability of salicylate to inhibit arachi-
donic acid metabolism and activation of nuclear factor-kB is 
well known, not all of the effects of salicylate are mediated by 
these pathways. Moreover, aspirin has been shown in animal 
models and clinical studies to have metabolic effects, including 
lowering of lipid levels and improved insulin sensitivity, that 
occur via unknown mechanisms. Hawley et al. studied whether 
salicylate can alter signaling by adenosine monophosphate-
activated protein kinase (AMPK), a critical cellular energy sen-
sor. They found that salicylate activated AMPK in cultured 
cells, resulting in phosphorylation of the AMPK a-subunit and 
AMPK target molecules including acetyl–coenzyme A carbox-
ylase (ACC, a regulator of fat oxidation), which occurred inde-
pendently of effects on mitochondrial adenosine triphosphate 
synthesis. They also demonstrated that salicylate increased 
levels of phosphorylated AMPK by inhibiting AMPK dephos-
phorylation, an effect that is dependent on a serine residue in 
the AMPK b1-subunit. Further studies in mice demonstrated 
that salicylate administration activated AMPK in hepatocytes, 
adipocytes, and muscle cells of wild-type mice, but cells from 
AMPK b1-subunit knockout mice did not activate AMPK or 
ACC after salicylate injection. Importantly, salicylate increased 
fat utilization in normal wild-type mice and improved insulin 
sensitivity in wild-type mice rendered obese by high-fat diets. 
These salutary effects of salicylate were abolished in AMPK 
b1-subunit knockout mice (Figure).
Some currently used medications, including metformin, are 
thought to exert their metabolic effects, in part, via activation 
of AMPK. This study is important because it is the first to 
demonstrate that salicylate-induced AMPK activation occurs 
independently of effects on adenosine triphosphate production 
and that salicylate-induced AMPK activation can have benefi-
cial metabolic effects that may be clinically relevant.
Michael Ross
Role of intensive glucose control in 
development of renal end points in 
type 2 diabetes mellitus: systematic 
review and meta-analysis
Coca et al., Arch Intern Med 2012; 172: 761–769; doi:10.1001/
archinternmed.2011.2230
Diabetic kidney disease is the leading cause of end-stage renal 
disease (ESRD) worldwide, and controlling hyperglycemia and 
hypertension currently is the main focus of diabetic kidney 
disease management. Thus, Coca et al. conducted a systematic 
review to summarize the benefits of intensive glucose control 
for diabetic kidney disease. A database search for randomized 
trials in patients with type 2 diabetes receiving intensive glu-
cose control versus those receiving conventional glucose control 
identified seven trials involving 28,065 adults. Compared with 
conventional control, intensive glucose control reduced surrogate 
markers such as development of microalbuminuria (hazard ratio, 
0.86; 95% confidence interval, 0.76–0.96) and macroalbuminu-
ria (hazard ratio, 0.74; 95% confidence interval, 0.65–0.85), but 
not hard outcomes such as doubling of serum creatinine, ESRD, 
and death from renal disease. The pooled cumulative incidence 
of doubling of serum creatinine, ESRD, and death from renal 
disease was very low (<4%, <1.5%, and <0.5%, respectively) com-
pared with that of the surrogate end points of microalbuminuria 
(23%) and macroalbuminuria (5%). The authors emphasized the 
benefit of intensive glucose control to reduce the risk of micro-
albuminuria and macroalbuminuria. In contrast, interpretation 
of the failure to demonstrate the benefits of intensive glycemic 
control for clinical renal outcomes, such as doubling of serum 
creatinine, ESRD, and death from renal disease, needs more cau-
tion. Clinical trials with hard end points such as diabetic kidney 
failure have rarely been conducted, because they would require 
impractically large, long-duration, and expensive studies.
The studies included in this meta-analysis may be too brief 
to address the effects of intensive therapy on the hard out-
comes (the median duration of follow-up was 2–8 years), 
with the possible exception of the United Kingdom Prospec-
tive Diabetes Study long-term follow-up. This is reflected 
by the low incidence of the hard outcomes, as the authors 
acknowledged. We should not underestimate the importance 
of good glucose control in preventing diabetic kidney disease 
on the basis of the failure to demonstrate the benefits of inten-
sive glycemic control for clinical renal outcomes.
Masaomi Nangaku
Fatty acid utilization in vivo.
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Mechanism and prevention of 
acute kidney injury from cast 
nephropathy in a rodent model
Ying et al., J Clin Invest 2012; 122: 1777–1785; doi:10.1172/JCI46490
Cast nephropathy is a frequent complication of multiple mye-
loma and occurs when the monoclonal light chain produced 
by myeloma cells binds to uromodulin/Tamm–Horsfall glyco-
protein, the most abundant protein in human urine. Binding 
between the two proteins causes their co-precipitation in the 
tubular lumen of the ascending limb of the loop of Henle, in 
the form of tubular casts that frequently display a fragmented 
appearance and are surrounded by an inflammatory cellular 
reaction. Obstruction of the tubular lumen by these casts causes 
rapid decline of renal function. If not removed, the casts acti-
vate an inflammatory response that amplifies the damage and 
makes it irreversible. For these reasons, cast nephropathy highly 
contributes to morbidity and mortality of myeloma patients. 
The group of Paul W. Sanders has been investigating these phe-
nomena since 1985 and has produced major contributions to 
the field, through the identification of light-chain binding to 
uromodulin as the mechanism of cast formation, the charac-
terization of the molecular binding sites of the two molecules, 
and the study of molecular mechanisms of light-chain tubular 
toxicity. The study of Ying et al. contributes significantly to fur-
thering the body of knowledge. The authors analyzed by yeast 
two-hybrid assay the binding of 20 diverse complementarity-
determining region 3 light-chain sequences to uromodulin, and 
classified peptide binding sequences according to their affinity. 
They also described the relevance of amino acid residues in 
determining the binding, and proposed a theoretical model that 
predicts the ionic interaction between the two molecules. On 
the basis of these data, the authors were then able to synthesize 
inhibitory peptides that dose-dependently inhibited light-chain 
binding in vitro. By cyclizing of these peptides, the inhibitory 
action was further increased, as demonstrated by competitive 
ELISA and far-Western experiments. Most interesting was the 
in vivo part of the study. Administration of an inhibitory pep-
tide proved useful not only in preventing but also in treating 
cast formation in a rat model of cast nephropathy induced by 
intraperitoneal injection of cast-forming light chains obtained 
from myeloma patients.
Though it is early to predict the potential clinical applica-
tion of inhibitory peptides, there is no doubt that the results 
presented in this manuscript are the first successful treatment 
for cast nephropathy, independent of the reduction of circu-
lating monoclonal light chains.
Maria Pia Rastaldi
Screening for, monitoring of, 
and treatment of chronic kidney 
disease stages 1 to 3: a systematic 
review for the US Preventive 
Services Task Force and for an 
American College of Physicians 
clinical practice guideline
Fink et al., Ann Intern Med 2012; 156: 570–581
Do screening and monitoring for chronic kidney disease 
(CKD) lead to earlier interventions that improve clinical 
outcomes? Many screening programs have been completed 
or are in progress worldwide, with the ostensible purpose of 
slowing progression and decreasing mortality. Fink et al. per-
formed a Medline search for English-language randomized 
controlled trials (RCTs) that evaluated screening for, mon-
itoring of, or treatment of CKD and also reported clinical 
outcomes. Not surprisingly, 110 trials evaluated treatments 
with the (expected) favorable outcomes in end-stage renal 
disease, mainly with the use of blockers of the renin–angioten-
sin system (primarily in macroalbuminuric diabetics). Other 
treatment trials showed possible benefits of beta-blockers 
in CKD patients with congestive heart failure and statins 
in hyperlipidemic/CKD patients. What is surprising is that 
no RCTs reported outcomes for the following questions: “In 
asymptomatic adults, what evidence is there that systematic 
CKD screening improves clinical outcomes or is associated 
with harms?” and “In adults with CKD stages 1 to 3, what 
evidence is there that systematic monitoring for worsening 
kidney function and/or kidney damage improves clinical out-
comes or is associated with harms?”
The lack of outcome data on screening and monitoring 
highlights the urgent need for well-controlled RCTs to justify 
the expense and effort of screening programs and perhaps 
nephrology referral in early and moderate kidney disease.
Jai Radhakrishnan
